(Q37874887)

24 August 2017

1 reference

title

Diagnosis and management of urothelial carcinoma of the bladder (English)

1 reference

24 August 2017

0 references

Maria F Tanaka

1

1 reference

24 August 2017

Guru Sonpavde

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

24 August 2017

13

1 reference

based on heuristic

inferred from page(s)

published in

Postgraduate Medicine

1 reference

24 August 2017

123

1 reference

24 August 2017

3

1 reference

24 August 2017

43-55

1 reference

24 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Cigarette smoking: cancer risks, carcinogens, and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Aromatic amines and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Chemotherapy-induced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Occupation and bladder cancer among men in Western Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Use of permanent hair dyes and bladder-cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Generation and reproductive phenotypes of mice lacking estrogen receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Gender, racial and age differences in bladder cancer incidence and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Gonorrhoea and male bladder cancer in a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Bladder cancer: translating molecular genetic insights into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

The impact of variant histology on the outcome of bladder cancer treated with curative intent

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

The 2004 WHO classification of bladder tumors: a summary and commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Histologic grading of noninvasive papillary urothelial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

A side by side comparison of cytology and biomarkers for bladder cancer detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Non-invasive diagnostic tests for bladder cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Urinary bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Use of nomograms as predictive tools in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Generation of a concise gene panel for outcome prediction in urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.05.2283

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.05.2283

1 reference

release_xcxvmcxnf5cghi3punguqdhggm

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xcxvmcxnf5cghi3punguqdhggm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference